Membranous expression of activated leukocyte cell adhesion molecule contributes to poor prognosis and malignant phenotypes of non-small-cell lung cancer

Journal of Surgical Research

Volumn 179, Issue 1, 2013, Pages 24-32

  Ishiguro, Futoshi ^a,b   Murakami, Hideki ^a   Mizuno, Tetsuya ^a,b   Fujii, Makiko ^a   Kondo, Yutaka ^a   Usami, Noriyasu ^b   Taniguchi, Tetsuo ^b   Yokoi, Kohei ^b   Osada, Hirotaka ^a,b   Sekido, Yoshitaka ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Activated leukocyte cell adhesion molecule; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; SHORT HAIRPIN RNA;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; CYTOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING;

EID: 84870712387     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2012.08.044     Document Type: Article

References (27)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69
2. N. Sawabata, E. Miyaoka, and H. Asamura Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade J Thorac Oncol 6 2011 1229
3. C.N. Oldenhuis, S.F. Oosting, and J.A. Gietema Prognostic versus predictive value of biomarkers in oncology Eur J Cancer 44 2008 946
4. L.C. van Kempen, J.M. Nelissen, and W.G. Degen Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction J Biol Chem 276 2001 25783
5. J.W. van Kilsdonk, R.H. Wilting, and M. Bergers Attenuation of melanoma invasion by a secreted variant of activated leukocyte cell adhesion molecule Cancer Res 68 2008 3671
6. D.S. Heffron, and J.A. Golden DM-GRASP is necessary for nonradial cell migration during chick diencephalic development J Neurosci 20 2000 2287
7. K. Ikeda, and T. Quertermous Molecular isolation and characterization of a soluble isoform of activated leukocyte cell adhesion molecule that modulates endothelial cell function J Biol Chem 279 2004 55315
8. U.H. Weidle, D. Eggle, S. Klostermann, and G.W. Swart ALCAM/CD166: cancer-related issues Cancer Genomics Proteomics 7 2010 231
9. L.C. van Kempen, J.J. van den Oord, and G.N. van Muijen Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin Am J Pathol 156 2000 769
10. W. Weichert, T. Knösel, and J. Bellach ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival J Clin Pathol 57 2004 1160
11. S. Ishigami, S. Ueno, and T. Arigami Clinical implication of CD166 expression in gastric cancer J Surg Oncol 103 2011 57
12. C. Kahlert, H. Weber, and C. Mogler Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse Br J Cancer 101 2009 457
13. J.A. King, S.F. Ofori-Acquah, and T. Stevens Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator Breast Cancer Res 6 2004 478
14. K. Tomita, A. van Bokhoven, and C.F. Jansen Activated leukocyte cell adhesion molecule (ALCAM) expression is associated with poor prognosis for bladder cancer patients UroOncology 3 2003 121
15. D. Mezzanzanica, M. Fabbi, and M. Bagnoli Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients Clin Cancer Res 14 2008 1726
16. A. Verma, N.K. Shukla, and S.V. Deo MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma Oncology 68 2005 462
17. M. Sawhney, A. Matta, and M.A. Macha Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients Int J Cancer 124 2009 2098
18. P. Goldstraw Staging manual in thoracic oncology 2009 IASLC Denver
19. W.D. Travis, E. Brambilla, and H. Muller-Hermelink Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon
20. K. Kawaguchi, H. Murakami, and T. Taniguchi Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells Carcinogenesis 30 2009 1097
21. H. Murakami, T. Mizuno, and T. Taniguchi LATS2 is a tumor suppressor gene of malignant mesothelioma Cancer Res 71 2011 873
22. A. Soltermann, R. Ossola, and S. Kilgus-Hawelski N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics Cancer 114 2008 124
23. W.C. Zhang, N. Shyh-Chang, and H. Yang Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis Cell 148 2012 259
24. P.R. Sudhir, C.H. Chen, and M.P. Kumari Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells Mol Cell Proteomics 2012 Jul 3 [Epub ahead of print]
25. K. Tomita, A. van Bokhoven, and C.F. Jansen Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin Biochem Biophys Res Commun 267 2000 870
26. P.C. Lunter, J.W. van Kilsdonk, and H. van Beek Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity Cancer Res 65 2005 8801
27. G. Cox, J.L. Jones, and K.J. O'Byrne Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer Clin Cancer Res 6 2000 2349